Seattle Genetics, Inc. operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seattle Genetics with three other
companies in this sector in the United States:
PDL Biopharma, Inc.
sales of $244.30 million
of which 87%
was Income generating assets),
Acorda Therapeutics, Inc.
of which 100%
was Zanaflex), and
of which 64%
During the year ended December of 2016, sales at
Seattle Genetics were $418.15 million.
increase of 24.2%
versus 2015, when the company's sales were $336.80 million.
This was the fifth consecutive year of sales increases at Seattle Genetics
(and since 2011, sales have increased a total of 341%).